Study summary · research use only
Medical Treatment of Female Sexual Dysfunction
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This narrative review discusses medical treatment approaches for female sexual dysfunction (FSD) in humans, describing it as comprising multiple overlapping sexual disorders with causes spanning biological, psychological, and social factors. The authors describe a multidisciplinary therapeutic approach including pharmacologic and nonpharmacologic management, and note that flibanserin and bremelanotide are psychoactive agents indicated for generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women, transdermal testosterone is used for HSDD in postmenopausal women, and menopause hormone therapy (systemic and local) is used for individualized management of women at midlife.
Abstract
Female sexual dysfunction (FSD) comprises multiple overlapping sexual disorders with a multifaceted cause within the frame of the biopsychosocial model. Health care providers can screen for FSD according to their level of expertise and deliver at least basic counseling before eventually referring to sexual medicine specialists for specific care. The therapeutic algorithm comprises a multidisciplinary approach, including pharmacologic and nonpharmacologic management. Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women, whereas transdermal testosterone is effective on HSDD in postmenopausal women. Menopause hormone therapy (systemic and local) is the mainstay for individualized management of women at midlife.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.